WO2000024359A3 - Use of gndf for treating retinal degeneration - Google Patents

Use of gndf for treating retinal degeneration Download PDF

Info

Publication number
WO2000024359A3
WO2000024359A3 PCT/FR1999/002586 FR9902586W WO0024359A3 WO 2000024359 A3 WO2000024359 A3 WO 2000024359A3 FR 9902586 W FR9902586 W FR 9902586W WO 0024359 A3 WO0024359 A3 WO 0024359A3
Authority
WO
WIPO (PCT)
Prior art keywords
gndf
retinal degeneration
treating retinal
treating
glyal
Prior art date
Application number
PCT/FR1999/002586
Other languages
French (fr)
Other versions
WO2000024359A2 (en
Inventor
Jose Sahel
Maria Frasson
Serge Picaud
David Hicks
Said Saddek Mohand
Thierry Leveillard
Original Assignee
Univ Pasteur
Jose Sahel
Maria Frasson
Serge Picaud
David Hicks
Said Saddek Mohand
Thierry Leveillard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pasteur, Jose Sahel, Maria Frasson, Serge Picaud, David Hicks, Said Saddek Mohand, Thierry Leveillard filed Critical Univ Pasteur
Priority to AU63456/99A priority Critical patent/AU6345699A/en
Publication of WO2000024359A2 publication Critical patent/WO2000024359A2/en
Publication of WO2000024359A3 publication Critical patent/WO2000024359A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention concerns the use of the neurotrophic factor derived from glyal cells (GNDF), or a substance of the family comprising said factor, as active protective agent for treating retinal degeneration, more particularly pigmentary retinopathy (RP) in human beings.
PCT/FR1999/002586 1998-10-26 1999-10-25 Use of gndf for treating retinal degeneration WO2000024359A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63456/99A AU6345699A (en) 1998-10-26 1999-10-25 Use of gndf for treating retinal degeneration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9813473A FR2784898A1 (en) 1998-10-26 1998-10-26 USE OF GDNF FOR THE TREATMENT OF RETINAL DEGENERATION
FR98/13473 1998-10-26

Publications (2)

Publication Number Publication Date
WO2000024359A2 WO2000024359A2 (en) 2000-05-04
WO2000024359A3 true WO2000024359A3 (en) 2000-08-10

Family

ID=9532057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1999/002586 WO2000024359A2 (en) 1998-10-26 1999-10-25 Use of gndf for treating retinal degeneration

Country Status (3)

Country Link
AU (1) AU6345699A (en)
FR (1) FR2784898A1 (en)
WO (1) WO2000024359A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823221B1 (en) 2001-04-06 2004-04-02 Univ Pasteur SEQUENCES ASSOCIATED WITH RETINAL DEGENERATION AND APPLICATIONS
EP1262188A1 (en) * 2001-05-22 2002-12-04 Centre National De La Recherche Scientifique (Cnrs) Improved neuronal gene transfer
WO2004030693A1 (en) * 2002-10-01 2004-04-15 Paola Ammannati Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition in form of a kit
EP2140004B1 (en) * 2007-04-12 2022-01-12 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Genetic suppression and replacement
ITUB20169937A1 (en) 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF PIGMENTAL RETINITIS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019694A1 (en) * 1995-11-29 1997-06-05 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997019694A1 (en) * 1995-11-29 1997-06-05 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (gdnf) protein product

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 1998 (1998-06-01), CARWILE MARY E ET AL: "Rod outer segment maintenance is enhanced in the presence of bFGF, CNTF and GDNF.", XP002135774, Database accession no. PREV199800399007 *
EXPERIMENTAL EYE RESEARCH JUNE, 1998, vol. 66, no. 6, June 1998 (1998-06-01), pages 791 - 805, ISSN: 0014-4835 *
J. SAHEL ET AL.: "Glial cel line-derived neurotrophic factor (GDNF) induces histological and functional neuroprotection of rod photoreceptors in the retinal degeneration (rd) mouse.", INVESTIGATIVE OPHTHALMOLOGY & VISUL SCIENCE, vol. 40, no. 4, 15 March 1999 (1999-03-15), ST. LOUIS, US, pages S966, XP000891599 *
M. FRASSON ET AL.: "Glial cell line-derived neurotrophic factor induces histologic and functional protection of rod photoreceptors in the rd/rd mouse.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 40, no. 11, October 1999 (1999-10-01), ST. LOUIS, US, pages 2724 - 2734, XP000891598 *

Also Published As

Publication number Publication date
WO2000024359A2 (en) 2000-05-04
AU6345699A (en) 2000-05-15
FR2784898A1 (en) 2000-04-28

Similar Documents

Publication Publication Date Title
WO2003053383A3 (en) Cosmetic use of at least a hydrophobin for treating keratinous materials
WO1999048482A3 (en) Smilagenin and anzurogenin-d for the treatment of alzheimer's disease
CZ20022079A3 (en) Fungicidal combinations of active substances, method of fighting fungi and use of such combinations of the active substances
AU1565300A (en) Anti-germinating method for tubers and bulbs using eugenol and/or isoeugenol
AU1393000A (en) 1,4-diazabicyclo(3.2.2)nonane derivatives, their preparation and therapeutic application
WO2003020226A3 (en) Cosmetic compositions comprising nanoparticles and processes for using the same
MXPA03005893A (en) Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs.
UA43378C2 (en) Composition for treating the respiratory distress- syndrome of the newborns and respiratory distress- syndrome of the adult
AU1392900A (en) 2,5-diazabicyclo(2.2.1)heptane derivatives, their preparation and therapeutic uses
AU2219795A (en) Use of maillard reaction inhibitors for the treatment of amyloidosis-based disease
WO1999032158A3 (en) Aminobiguanides to disinfect contact lenses and preserve pharmaceutical compositions
MXPA00013021A (en) Carotene analog of porhyrins, chlorins and bacteriochlorins as therapeutic and diagnostic agents.
ZA97910B (en) Mixtures which can be isolated from Eugenia Jambolana Lamarck seeds, their preparation and their use as medicaments.
EE200300504A (en) Preparations of 3,7-diazabicyclo [3.3.1], methods for their preparation and their use in the prophylaxis or treatment of cardiac arrhythmias
HUP0302538A3 (en) 3,7-diazabicyclo[3.3.0]oczanes and their use in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them
WO2000024359A3 (en) Use of gndf for treating retinal degeneration
AU4262599A (en) Preparation for treating human skin and human hair comprising a special active ingredient combination, and the use of this active ingredient combination
MY118687A (en) Breathable absorbent articles
HUP0004637A3 (en) Ketone peroxide derivatives, their preparation and use
WO1998000119A3 (en) Applications of active substances affecting the functions of non neuronal acetylcholine
AU2001296173A1 (en) 3,8-diazabicyclo(3.2.1)octanes and their use in the treatment of cardiac arrhythmias
AU4747497A (en) Sordarin derivatives
EE200300495A (en) Preparations of 3,7-diazabicyclo [3.3.1], methods for their preparation and their use in the prophylaxis or treatment of cardiac arrhythmias
WO2002029099A1 (en) Method of screening physiologically active substance
EE200300506A (en) Preparations of 3,7-diazabicyclo [3.3.1], methods for their preparation and their use in the prophylaxis or treatment of cardiac arrhythmias

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref country code: AU

Ref document number: 1999 63456

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase